Mitoglitazone

Mitoglitazone

SCHEMBL18541503

CCc1ccc(C(=O)COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 14/20 1.00
MPC2 O95563 2/20 1.00
CYP2C8 P10632 2/20 1.00
CYP2C9 P11712 2/20 1.00
CYP3A4 P08684 2/20 0.66
RXRA P19793 1/20 0.66
FFAR1 O14842 4/20 0.52
PPARA Q07869 2/20 0.52
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
KMT2A Q03164 1/20 0.51
HSD17B10 Q99714 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
HRH3 Q9Y5N1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mitoglitazone SCHEMBL622605 1.00 PPARG (1.00) PPARGMPC2CYP2C8CYP2C9CYP3A4
Mitoglitazone SCHEMBL18538169 1.00 PPARG (1.00) PPARGMPC2CYP2C8CYP2C9CYP3A4
Mitoglitazone SCHEMBL18541482 1.00 PPARG (1.00) PPARGMPC2CYP2C8CYP2C9CYP3A4
Mitoglitazone SCHEMBL2221702 0.99 PPARG (0.98) PPARGMPC2CYP2C8CYP2C9CYP3A4
Mitoglitazone SCHEMBL2221427 0.96 PPARG (0.92) PPARGMPC2CYP2C8CYP2C9CYP3A4
SCHEMBL14413449 0.91 PPARG (0.83) PPARGMPC2CYP2C8CYP2C9CYP3A4
SCHEMBL19828529 0.90 PPARG (0.81) PPARGMPC2CYP2C8CYP2C9CYP3A4
SCHEMBL19416499 0.89 PPARG (0.80) PPARGMPC2CYP2C8CYP2C9CYP3A4
SCHEMBL10085212 0.88 PPARG (0.79) PPARGMPC2CYP2C8CYP2C9CYP3A4
SCHEMBL10119002 0.88 PPARG (0.79) PPARGMPC2CYP2C8CYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220211682-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME DEUTERX, LLC 2022-07-07 US disclosed
US-11123336-B2 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same POXEL SA (FR) 2021-09-21 US disclosed
US-10265305-B2 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same POXEL SA (FR) 2019-04-23 US disclosed
US-20180133204-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME POXEL SA (FR) 2018-05-17 US disclosed
US-20180133204-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME POXEL SA (FR) 2018-05-17 US disclosed
EP-2968298-B1 DEUTERIUM-ENRICHED 2,4-THIAZOLIDINEDIONES AND METHODS OF TREATMENT DEUTERX LLC (US) 2018-01-31 EP disclosed
US-9833445-B2 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same DEUTERX, LLC (US) 2017-12-05 US disclosed
US-9833445-B2 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same DEUTERX, LLC (US) 2017-12-05 US disclosed
US-20170049762-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME POXEL SA (FR) 2017-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10265305-B2 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same SLC5A2, PPARD, DPP4 PPARG 10/4885MPC2 636/4885CYP2C8 443/4885
US-20220211682-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SLC5A2, PPARD, DPP4 PPARG 10/4885MPC2 636/4885CYP2C8 443/4885
US-20180133204-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SLC5A2, PPARD, DPP4 PPARG 10/4885MPC2 636/4885CYP2C8 443/4885
US-11123336-B2 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same SLC5A2, PPARD, DPP4 PPARG 10/4885MPC2 636/4885CYP2C8 443/4885
US-20170049762-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SLC5A2, PPARD, DPP4 PPARG 10/4885MPC2 636/4885CYP2C8 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.